See more : Skyline Investment S.A. (SKL.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Adlai Nortye Ltd. American Depositary Shares (ANL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adlai Nortye Ltd. American Depositary Shares, a leading company in the Biotechnology industry within the Healthcare sector.
- Kyushu Electric Power Company, Incorporated (KYSEY) Income Statement Analysis – Financial Results
- St. Modwen Properties Limited (1IG.F) Income Statement Analysis – Financial Results
- Kidpik Corp. (PIK) Income Statement Analysis – Financial Results
- Blackline Safety Corp. (BLN.TO) Income Statement Analysis – Financial Results
- Irving Resources Inc. (IRV.CN) Income Statement Analysis – Financial Results
Adlai Nortye Ltd. American Depositary Shares (ANL)
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.00M | 0.00 | 45.73M | 0.00 | 0.00 |
| Cost of Revenue | 2.22M | 2.04M | 0.00 | 1.51M | 1.48M |
| Gross Profit | 2.78M | -2.04M | 45.73M | -1.51M | -1.48M |
| Gross Profit Ratio | 55.56% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 58.15M | 54.49M | 42.11M | 19.04M | 13.34M |
| General & Administrative | 15.29M | 13.04M | 12.45M | 6.52M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | -968.12K | 0.00 |
| SG&A | 15.29M | 13.04M | 12.45M | 5.56M | 4.30M |
| Other Expenses | 0.00 | 7.88M | -46.77M | 0.00 | 0.00 |
| Operating Expenses | 72.55M | 67.27M | 54.37M | 24.59M | 17.64M |
| Cost & Expenses | 73.38M | 67.27M | 54.37M | 26.10M | 19.12M |
| Interest Income | 61.95K | 550.00K | 32.00K | 24.05K | 22.87K |
| Interest Expense | 791.00K | 433.00K | 579.00K | 1.75M | 466.15K |
| Depreciation & Amortization | 2.22M | 2.04M | 1.83M | 1.51M | 1.48M |
| EBITDA | -101.22M | -65.41M | -7.01M | -24.59M | -17.64M |
| EBITDA Ratio | -2,026.06% | 0.00% | -118.84% | 0.00% | 0.00% |
| Operating Income | -67.55M | -67.27M | -8.65M | -26.10M | -19.12M |
| Operating Income Ratio | -1,352.20% | 0.00% | -18.91% | 0.00% | 0.00% |
| Total Other Income/Expenses | -36.68M | 8.48M | -48.03M | -37.28M | 1.29M |
| Income Before Tax | -104.23M | -58.79M | -56.68M | -63.38M | -17.83M |
| Income Before Tax Ratio | -2,086.37% | 0.00% | -123.95% | 0.00% | 0.00% |
| Income Tax Expense | 643.00K | 8.31M | -46.19M | 3.00 | -1.00 |
| Net Income | -104.87M | -58.79M | -56.68M | -63.38M | -17.83M |
| Net Income Ratio | -2,099.25% | 0.00% | -123.95% | 0.00% | 0.00% |
| EPS | -7.26 | -6.93 | -6.68 | -7.64 | -2.10 |
| EPS Diluted | -7.26 | -6.93 | -6.68 | -7.64 | -2.10 |
| Weighted Avg Shares Out | 14.45M | 8.48M | 8.48M | 8.48M | 8.48M |
| Weighted Avg Shares Out (Dil) | 14.45M | 8.48M | 8.48M | 8.48M | 8.48M |
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday - Coinbase Glb (NASDAQ:COIN), Adlai Nortye (NASDAQ:ANL)
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles
Source: https://incomestatements.info
Category: Stock Reports